AASLD – The Liver Meeting 2022

infohep news

• Hepatitis C elimination

  Only 11 countries on target to eliminate hepatitis C by 2030

  Keith Alcorn / 15 November 2022

  Only 11 countries are on course to meet their goals for elimination of hepatitis C by 2030, while five countries with the highest burdens of hepatitis C are unlikely to achieve elimination ...

• Treatment for people who use drugs

  UK community test-and-treat service achieves high hepatitis C cure rate in people who use drugs

  Keith Alcorn / 15 November 2022

  Offering hepatitis C testing and treatment through a community drugs and alcohol service led to high uptake of testing and treatment among current and former injecting drug users, as well as a ...

• Mother to child

  Simplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B

  Keith Alcorn / 14 November 2022

  A simplified regimen for the prevention of mother-to-child transmission of hepatitis B was just as effective as the standard preventive regimen in pregnant women with very high virus levels and is likely ...

• New and experimental treatments for hepatitis B

  VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B

  Keith Alcorn / 14 November 2022

  The experimental hepatitis B antiviral VIR-2218 shows potent activity against the virus when combined with either a monoclonal antibody that targets three steps in the hepatitis B lifecycle, or pegylated interferon, two studies ...

• New and experimental treatments for hepatitis B

  Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five

  Keith Alcorn / 14 November 2022

  Up to one in five people with hepatitis B treated with the experimental antiviral bepirovirsen achieved a sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA, a sign indicating the ...